Commission Delegated Regulation (EU) 2022/692 of 16 February 2022 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

COMMISSION DELEGATED REGULATION (EU) 2022/692

of 16 February 2022

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

(Text with EEA relevance)

Article 1

Amendments to Regulation (EC) No 1272/2008

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

It shall apply from 1 December 2023.

By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

ANNEX

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1) in Part 3, Table 3 is amended as follows: (a) the following entries are inserted: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M- factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘014-052-00-7 silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide 272-697-1 68909-20-6 STOT RE 2 H373 (lungs) (inhalation) GHS08 Wng H373 (lungs) (inhalation) EUH066’ ‘035-005-00-7 ammonium bromide 235-183-8 12124-97-9 Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2 H360FD H362 H336 H372 (nervous system) H319 GHS08 GHS07 Dgr H360FD H362 H336 H372 (nervous system) H319’ ‘050-032-00-4 dibutyltin bis(2-ethylhexanoate) 220-481-2 2781-10-4 Muta. 2 Repr. 1B STOT RE 1 H341 H360FD H372 (immune system) GHS08 Dgr H341 H360FD H372 (immune system)’ ‘050-033-00-X dibutyltin di(acetate) 213-928-8 1067-33-0 Muta 2 Repr. 1B STOT RE 1 H341 H360FD H372 (immune system) GHS08 Dgr H341 H360FD H372 (immune system)’ ‘052-001-00-0 tellurium 236-813-4 13494-80-9 Repr. 1B Lact. H360Df H362 GHS08 Dgr H360Df H362’ ‘052-002-00-6 tellurium dioxide 231-193-1 7446-07-3 Repr. 1B Lact. H360Df H362 GHS08 Dgr H360Df H362’ ‘056-005-00-3 barium diboron tetraoxide 237-222-4 13701-59-2 Repr. 1B Acute Tox. 4 Acute Tox. 3 H360FD H332 H301 GHS08 GHS06 Dgr H360FD H332 H301

inhalation: ATE = 1,5 mg/L (dusts or mists) oral: ATE = 100 mg/kg bw’ ‘601-097-00-8 Propylbenzene 203-132-9 103-65-1 Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 H226 H304 H335 H411 GHS02 GHS08 GHS07 GHS09 Dgr H226 H304 H335 H411’ ‘603-243-00-6 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol 253-057-0 36483-57-5; 1522-92-5 Carc. 1B Muta. 2 H350 H341 GHS08 Dgr H350 H341’ ‘604-096-00-0 piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether 200-076-7 51-03-6 STOT SE 3 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H335 H319 H400 H410 GHS07 GHS09 Wng H335 H319 H410 EUH066 M = 1 M = 1’ ‘604-097-00-6 2,4,6-tri-tert-butylphenol 211-989-5 732-26-3 Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B H360D H302 H373 (liver) H317 GHS08 GHS07 Dgr H360D H302 H373 (liver) H317

oral: ATE = 500 mg/kg bw’ ‘604-098-00-1 4,4'-sulphonyldiphenol; bisphenol S 201-250-5 80-09-1 Repr. 1B H360FD GHS08 Dgr H360FD’ ‘606-153-00-5 benzophenone 204-337-6 119-61-9 Carc. 1B H350 GHS08 Dgr H350’ ‘606-154-00-0 quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone 220-529-2 2797-51-5 Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H302 H373 (blood system, kidneys) H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H302 H373 (blood system, kidneys) H319 H317 H410

oral: ATE = 500 mg/kg bw M = 10 M = 10’ ‘607-756-00-6 exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate 227-561-6 5888-33-5 Skin Sens. 1A H317 GHS07 Wng H317’ ‘607-757-00-1 daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid 216-485-9 1596-84-5 Carc. 2 H351 GHS08 Wng H351’ ‘607-758-00-7 4,4'-oxydi(benzenesulphonohydrazide) 201-286-1 80-51-3 Self-react. D Aquatic Acute 1 Aquatic Chronic 1 H242 H400 H410 GHS02 GHS09 Dgr H242 H410

M = 1 M = 1’ ‘607-759-00-2 toluene-4-sulphonohydrazide 216-407-3 1576-35-8 Self-react. D H242 GHS02 Dgr H242’ ‘607-760-00-8 2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124 239-203-6 15141-18-1 Skin Sens. 1A H317 GHS07 Wng H317

Skin Sens. 1A; H317: C ≥ 0,001 %’ ‘607-761-00-3 Perfluoroheptanoic acid; tridecafluoroheptanoic acid 206-798-9 375-85-9 Repr. 1B STOT RE 1 H360D H372 (liver) GHS08 Dgr H360D H372 (liver)’ ‘607-762-00-9 methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate - 283159-90-0 Carc. 2 Aquatic Chronic 2 H351 H411 GHS08 GHS09 Wng H351 H411’ ‘607-763-00-4 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts - - Repr. 1B Eye Irrit. 2 H360FD H319 GHS08 GHS07 Dgr H360FD H319’ ‘607-764-00-X 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid - 2156592-54-8 Repr. 1B Eye Irrit. 2 H360FD H319 GHS08 GHS07 Dgr H360FD H319’ ‘607-765-00-5 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid - - Repr. 1B H360FD GHS08 Dgr H360FD’ ‘613-341-00-0 clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine 277-728-2 74115-24-5 Aquatic Chronic 1 H410 GHS09 Wng H410

M = 1’ ‘613-342-00-6 theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione 200-385-7 58-55-9 Repr. 1B H360D GHS08 Dgr H360D’ ‘613-343-00-1 pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether - 179101-81-6 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410

M = 1 000 M = 100’ ‘613-344-00-7 Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione 223-296-5; 240-062-8 3811-73-2; 15922-78-8 Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2 H331 H311 H302 H372 (nervous system) H315 H319 H317 H400 H411 GHS06 GHS08 GHS09 Dgr H331 H311 H302 H372 (nervous system) H315 H319 H317 H410 EUH070 inhalation: ATE = 0,5 mg/L (dusts or mists) dermal: ATE = 790 mg/kg bw oral: ATE = 500 mg/kg bw M = 100’ ‘613-345-00-2 1,3,5-triazine-2,4,6-triamine; melamine 203-615-4 108-78-1 Carc. 2 STOT RE 2 H351 H373 (urinary tract) GHS08 Wng H351 H373 (urinary tract)’ ‘615-046-00-2 1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI] 220-474-4 2778-42-9 Resp. Sens. 1 Skin Sens. 1A H334 H317 GHS08 Dgr H334 H317’ ‘615-047-00-8 1,3-bis(isocyanatomethyl)benzene; [m-XDI] 222-852-4 3634-83-1 Resp. Sens. 1 Skin Sens. 1A H334 H317 GHS08 Dgr H334 H317

Skin Sens. 1A; H317: C ≥ 0,001 %’ ‘615-048-00-3 2,4,6-triisopropyl-m-phenylene diisocyanate 218-485-4 2162-73-4 Resp. Sens. 1 Skin Sens. 1 H334 H317 GHS08 Dgr H334 H317’ ‘615-049-00-9 1,5-naphthylene diisocyanate [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] 221-641-4 3173-72-6 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 H335 H315 H319 H334 H317 H412 GHS07 GHS08 Dgr H335 H315 H319 H334 H317 H412’ ‘615-050-00-4 1,5-naphthylene diisocyanate [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] 221-641-4 3173-72-6 Acute Tox. 2 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 H330 H335 H315 H319 H334 H317 H412 GHS06 GHS08 Dgr H330 H335 H315 H319 H334 H317 H412

inhalation: ATE = 0,27 mg/L (dusts or mists)’ ‘616-237-00-3 fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide - 239110-15-7 Repr. 2 H361d GHS08 Wng H361d’ ‘616-238-00-9 N-(2-nitrophenyl)phosphoric triamide 477-690-9 874819-71-3 Repr. 1B STOT RE 2 H360Fd H373 (kidneys) GHS08 Dgr H360Fd H373 (kidneys)’ ‘616-239-00-4 N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram - 1255734-28-1 Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H361f H332 H317 H400 H410 GHS08 GHS07 GHS09 Wng H361f H332 H317 H410

inhalation: ATE = 2,2 mg/L (dusts or mists) M = 10 M = 1’ ‘616-240-00-X Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam - 881685-58-1 Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H360D H317 H400 H410 GHS08 GHS07 GHS09 Dgr H351 H360D H317 H410

Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10’ ‘650-058-00-1 Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents] 283-644-7 84696-25-3 Repr. 2 Skin Sens. 1 Aquatic Chronic 1 H361d H317 H410 GHS08 GHS07 GHS09 Wng H361d H317 H410

M = 10’ (b) the entries corresponding to index numbers 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 are replaced by the following entries respectively: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M- factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘014-001-00-9 trichlorosilane 233-042-5 10025-78-2 Flam. Liq. 1 Water-react. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 H224 H260 H331 H302 H314 H318 GHS02 GHS06 GHS05 Dgr H224 H260 H331 H302 H314 EUH014 EUH029 EUH071 inhalation: ATE = 7,6 mg/L (vapour) oral: ATE = 1 000 mg/kg bw’ ‘023-001-00-8 divanadium pentaoxide; vanadium pentoxide 215-239-8 1314-62-1 Muta. 2 Carc. 1B Repr. 2 Lact. Acute Tox. 3 Acute Tox. 2 STOT SE 3 STOT RE 1 Aquatic Chronic 2 H341 H350 H361fd H362 H301 H330 H335 H372 (respiratory tract, inhalation) H411 GHS06 GHS08 GHS09 Dgr H341 H350 H361fd H362 H301 H330 H335 H372 (respiratory tract, inhalation) H411

inhalation: ATE = 0,05 mg/L (dusts or mists) oral: ATE = 220 mg/kg bw’ ‘601-024-00-X Cumene 202-704-5 98-82-8 Flam. Liq. 3 Carc. 1B Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 H226 H350 H304 H335 H411 GHS02 GHS08 GHS07 GHS09 Dgr H226 H350 H304 H335 H411’ ‘603-014-00-0 2-butoxyethanol; ethylene glycol monobutyl ether 203-905-0 111-76-2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 H331 H302 H315 H319 GHS06 Dgr H331 H302 H315 H319

inhalation: ATE = 3 mg/L (Vapours) oral: ATE = 1 200 mg/kg bw’ ‘603-107-00-6 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether 203-906-6 111-77-3 Repr. 1B H360D GHS08 Dgr H360D

Repr. 1B; H360D: C ≥ 3 %’ ‘604-030-00-0 4,4'-isopropylidenediphenol; bisphenol A 201-245-8 80-05-7 Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360F H335 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H360F H335 H318 H317 H410

M = 1 M = 10’ ‘607-111-00-9 2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate 239-701-3 15625-89-5 Carc. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H315 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H315 H319 H317 H410

M = 1 M = 1 D’ ‘607-230-00-6 2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex - - Repr. 1B H360D GHS08 Dgr H360D’ ‘607-253-00-1 cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 269-855-7 68359-37-5 Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H362 H330 H300 H370 (nervous system) H400 H410 GHS06 GHS08 GHS09 Dgr H362 H330 H300 H370 (nervous system) H410

inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 14 mg/kg bw M = 1 000 000 M = 1 000 000 ’ ‘607-254-00-7 beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate - 1820573-27-0 Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H362 H330 H300 H370 (nervous system) H400 H410 GHS06 GHS08 GHS09 Dgr H362 H330 H300 H370 (nervous system) H410

inhalation: ATE = 0,081 mg/L (dusts or mists) oral: ATE = 11 mg/kg bw M = 1 000 000 M = 1 000 000 ’ ‘607-734-00-6 pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate 404-290-3 7216-95-7 Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 H360D H332 H373 (inhalation) H319 GHS08 GHS07 Dgr H360D H332 H373 (inhalation) H319

Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists)’ ‘607-735-00-1 N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) 200-652-8 67-43-6 Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 H360D H332 H373 (inhalation) H319 GHS08 GHS07 Dgr H360D H332 H373 (inhalation) H319

Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists)’ ‘607-736-00-7 pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate 205-391-3 140-01-2 Repr. 1B Acute Tox. 4 STOT RE 2 H360D H332 H373 (inhalation) GHS08 GHS07 Dgr H360D H332 H373 (inhalation)

Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists)’ ‘608-032-00-2 acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine - 135410-20-7 160430-64-8 Repr. 2 Acute Tox. 3 Aquatic Chronic 1 Aquatic Acute 1 H361d H301 H410 H400 GHS08 GHS06 GHS09 Dgr H361d H301 H410

oral: ATE = 140 mg/kg bw M = 10 M = 10’ ‘609-042-00-X pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene 254-938-2 40487-42-1 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H400 H410 GHS08 GSH09 Wng H361d H410

M = 100 M = 10’ ‘613-012-00-1 bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide 246-585-8 25057-89-0 Repr. 2 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 H361d H302 H319 H317 GHS08 GHS07 Wng H361d H302 H319 H317

oral: ATE = 1 600 mg/kg bw’ ‘616-164-00-7 dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide

149961-52-4 Carc. 2 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H332 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H332 H410

inhalation: ATE = 1,3 mg/L (dusts or mists) M = 100 M = 100’ (c) the entry corresponding to index number 615-007-00-X is deleted.